Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt’s lead product, Episalvan®, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan® as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S.
UK Investor Show
Recognised as the UK’s top one day event for those serious about making money from shares, UK Investor is owned by the Wray family.
The Global Group UK Investor City forum has begun! CEO of RiverFort Group, Brian Kinane is kicking off tonight’s proceedings pic.twitter.com/PQZOXgZujw